Log In
Print
BCIQ
Print
Print this Print this
 

SynCon DNA HBV vaccine (INO-1800)

  Manage Alerts
Collapse Summary General Information
Company Inovio Pharmaceuticals Inc.
DescriptionSynthetic DNA vaccine encoding a recombinant consensus plasmid from genotype A through E of the hepatitis B core antigen (HBcAg)
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: DNA vaccine
Latest Stage of DevelopmentPhase I
Standard IndicationHepatitis B virus (HBV)
Indication DetailsTreat HBV infection
Regulatory Designation

Partner

Roche


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$422.5M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today